Arrowhead Pharmaceuticals Faces Setback as Exciting Kidney Treatment Progresses
Arrowhead Pharmaceuticals experienced a stock market decline followng mixed reactions to its clinical trial outcomes. ARO-C3 is an RNA interference therapeutic targeting
